ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

ClinicalTrials.gov ID: NCT03606174

Public ClinicalTrials.gov record NCT03606174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT03606174
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Mirati Therapeutics Inc.
Industry
Enrollment
260 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 10, 2018
Primary completion
Aug 2, 2022
Completion
Aug 21, 2022
Last update posted
Aug 23, 2023

2018 – 2022

United States locations

U.S. sites
36
U.S. states
23
U.S. cities
33
Facility City State ZIP Site status
The University of Arizona Cancer Center Tucson Arizona 85724
University of California Irvine Irvine California 92868
Rocky Mountain Cancer Centers Aurora Colorado 80012
Yale School of Medicine New Haven Connecticut 06510
SCRI - Florida Cancer Specialists- North Region St. Petersburg Florida 33705
Moffitt Cancer Center Tampa Florida 33612
SCRI - Florida Cancer Specialists - West Palm Beach West Palm Beach Florida 33401
The University of Chicago Chicago Illinois 60637
Indiana University - Melvin & Bren Simon Cancer Center Indianapolis Indiana 46202
Norton Cancer Institute - Broadway Louisville Kentucky 40202
Ochsner Cancer Institute New Orleans Louisiana 70121
Maryland Oncology Hematology, P.A. Lanham Maryland 20706
Dana Farber Cancer Institute Boston Massachusetts 02215
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201
Washington University School of Medicine - Siteman Cancer Center St Louis Missouri 63110
GU Research Network/Urology Cancer Center Omaha Nebraska 68130
Comprehensive Cancer Centers of Nevada - Southwest Las Vegas Nevada 89169
New York Oncology Hematology - Albany Medical Center Albany New York 12206
Roswell Park Cancer Institute Buffalo New York 14263
Northwell Health Monter Cancer Center Lake Success New York 11042
NYU Langone Laura & Isaac Perlmutter Cancer Center New York New York 10016
Memorial Sloan-Kettering Cancer Center New York New York 10065
New York-Presbyterian - Weill Cornell Medical Center New York New York 10065
University of North Carolina - Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599
Duke University Hospital Durham North Carolina 27710
The Ohio State University College of Medicine Columbus Ohio 43202
Allegheny General Hospital Pittsburgh Pennsylvania 15212
Vanderbilt University - Ingram Cancer Center Nashville Tennessee 37232
Texas Oncology-Austin Central Austin Texas 78731
Texas Oncology- Memorial City Houston Texas 77024
University of Texas - MD Anderson Cancer Center Houston Texas 77030
University of Texas Health Science Center San Antonio Texas 78229
Texas Oncology - Tyler Tyler Texas 75702
Virginia Cancer Specialists- Fairfax Fairfax Virginia 22031
Virginia Oncology Associates Norfolk Virginia 23502
Seattle Cancer Center Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03606174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 23, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03606174 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →